Hellinger F J
Division of Extramural Research, National Center for Health Services Research and Health Care Technology Assessment (NCHSR), Rockville, MD 20857.
Public Health Rep. 1988 May-Jun;103(3):309-19.
The personal medical care costs of those diagnosed with acquired immunodeficiency syndrome (AIDS) in 1988 are forecast to be $2.2 billion, an amount that will increase to $4.5 billion in 1991. This is the first study to include the cost of purchasing azidothymidine (AZT), also called zidovudine, a palliative treatment for AIDS. The forecasts of this study are lower than those reported by Rice and Scitovsky, and other researchers, because the data are more recent and AIDS patients are receiving more care on an outpatient basis and staying in the hospital fewer days. They are also lower because projections for the number of AIDS cases diagnosed in future years are lower than those made by the Centers for Disease Control (CDC). This study projects that about 38,000 AIDS cases will be diagnosed in 1988 and 73,000 in 1991. The projections in this study are derived using data on the number of AIDS cases reported to CDC from January 1984 to October 1987, while the CDC projections employed by Rice and Scitovsky were derived using data from June 1981 to May 1986. It is also projected that the lifetime cost of treating an AIDS patient will increase from $57,000 in 1988 to $61,800 in 1991 due to the wider use of AZT.
1988年被诊断出患有获得性免疫缺陷综合征(艾滋病)的患者个人医疗费用预计为22亿美元,到1991年这一数字将增至45亿美元。这是第一项将购买叠氮胸苷(AZT,也称为齐多夫定)的费用纳入其中的研究,AZT是一种艾滋病的姑息治疗药物。该研究的预测低于赖斯和西托夫斯基以及其他研究人员的报告,因为数据更新,且艾滋病患者在门诊接受的治疗更多,住院天数更少。预测较低还因为对未来几年诊断出的艾滋病病例数的预测低于疾病控制中心(CDC)的预测。该研究预计1988年将诊断出约38000例艾滋病病例,1991年为73000例。本研究中的预测是使用1984年1月至1987年10月向疾病控制中心报告的艾滋病病例数数据得出的,而赖斯和西托夫斯基采用的疾病控制中心的预测是使用1981年6月至1986年5月的数据得出的。此外,预计由于AZT的更广泛使用,治疗一名艾滋病患者的终身费用将从1988年的57000美元增至1991年的61800美元。